General Anesthetic
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About General Anesthetic
General Anesthetic drugs are a cornerstone of modern medicine, primarily used to induce a reversible loss of consciousness and sensation, enabling surgical procedures and other medical interventions. Their mechanism of action involves modulating neuronal activity in the central nervous system, leading to sedation, amnesia, analgesia, and immobility. The first-in-class general anesthetic, FORANE (isoflurane), was introduced by Baxter in 1979, marking a significant advancement in patient care during surgery. Since then, the field has seen the development of newer agents aimed at improving safety profiles, reducing side effects, and offering more tailored anesthetic experiences.
These agents are approved for inducing and maintaining general anesthesia in adults and children, facilitating procedures ranging from minor surgeries to complex operations. The evolution of general anesthetics has focused on achieving a balance between potent anesthetic effects and favorable pharmacokinetic properties, such as rapid onset and offset, to allow for precise control over the depth of anesthesia and quicker patient recovery.
The future of general anesthetics is likely to involve further refinement of existing agents, potentially through novel formulations or delivery methods, and continued research into understanding their precise molecular targets to minimize adverse effects and optimize patient outcomes. The ongoing pursuit is for agents that provide excellent anesthetic control with minimal systemic impact.
10 FDA-approved General Anesthetic drugs, including AMIDATE, with 27 active Phase 3 trials across 1 indication from 1 active sponsor. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved General Anesthetic Drugs
10 totalGeneral Anesthetic drugs have evolved significantly since the introduction of the first-in-class agent, FORANE (isoflurane), by Baxter in 1979. This early volatile anesthetic paved the way for subsequent generations of agents designed to improve upon its properties. AMIDATE (etomidate), approved in 1982 by Pfizer, offered an intravenous option with a different pharmacokinetic profile. Later developments included SUPRANE (desflurane) from Baxter in 1992 and ULTANE (sevoflurane) from AbbVie in 1995, both volatile agents that aimed for faster induction and emergence compared to earlier drugs. Individual general anesthetic drugs differentiate themselves through various clinical characteristics. For instance, sevoflurane and desflurane are known for their relatively rapid onset and offset, facilitating quicker patient recovery, while etomidate is often favored for induction in hemodynamically unstable patients due to its minimal cardiovascular impact. Propofol, introduced in 1999 by Dr. Reddy's, is an intravenous agent widely used for both induction and maintenance of anesthesia, as well as sedation, offering a distinct route of administration and rapid clearance. Today, the landscape of general anesthetics is largely dominated by generic and biosimilar versions of established drugs, with multiple manufacturers like GLAND, Dr. Reddy's, SHANGHAI HENGRUI, PIRAMAL CRITICAL, and others offering etomidate, propofol, sevoflurane, and desflurane. These agents are considered standard-of-care for a wide range of surgical procedures. While innovation in novel general anesthetic agents has slowed, the focus remains on optimizing the use of existing drugs and ensuring their accessibility and affordability in clinical practice.
General Anesthetic Indications in Trials
Active industry trialsGeneral Anesthetic activity in the active Phase 2/3 pipeline is currently limited, with only one active trial identified in the indication of General Anesthetic. This suggests a relatively quiet period for novel drug development within this specific therapeutic class at the late stages of clinical investigation. Given the limited active trials, there is not significant evidence of expansion into new indications or novel patient subpopulations being tested beyond the established use of general anesthesia. The current pipeline activity does not indicate a strong trend towards exploring combination regimens or new modalities such as oral formulations; the focus remains on established injectable or volatile anesthetic agents. Looking ahead to the next 6-12 months, the pipeline for general anesthetics appears to be thinning rather than rich with upcoming readouts. The single active trial represents the primary point of interest. The lack of broader activity in Phase 2 and Phase 3 trials suggests that significant breakthroughs or new entrants in the general anesthetic space are not imminent, and the field may be relying on incremental improvements or optimizations of existing therapies.
Top General Anesthetic Sponsors
Industry trials, any indicationHaisco Pharmaceutical Group Co., Ltd. is the dominant player in the current limited Phase 2/3 general anesthetic landscape, leading activity with one active trial. This indicates a focused effort by the company to advance a specific program within this therapeutic area, potentially representing a novel approach or an expansion of an existing agent. With only one active sponsor identified, there are no significant key challengers currently competing in the Phase 2/3 space for general anesthetics. The landscape is not characterized by multiple sponsors attacking the same indications or by originator-vs-follower dynamics in advanced trials. The strategic landscape for general anesthetics appears to be primarily focused on specific regional markets, with Haisco Pharmaceutical Group Co., Ltd. representing activity likely centered in Asia, given its origin. The limited late-stage pipeline suggests that major shifts in the competitive balance are unlikely in the short term. For investors or BD scouts, the current environment points towards a mature market with minimal disruptive innovation on the horizon, emphasizing the importance of understanding the specific goals and potential of Haisco's single active trial.
General Anesthetic Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved General Anesthetic drugs across 2 indications from 1 sponsor. Earliest readout: Q4 2024.
Coverage: trials whose intervention is an approved General Anesthetic drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.